In a report released today, Michael Higgins from Ladenburg maintained a Buy rating on Zogenix (ZGNX), with a price target of $50. The company’s shares closed yesterday at $38.19, close to its 52-week low of $33.43.
According to TipRanks.com, Higgins is ranked 0 out of 5 stars with an average return of -4.9% and a 31.8% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals Inc, Paratek Pharmaceuticals, and Zynerba Pharmaceuticals.
Currently, the analyst consensus on Zogenix is a Strong Buy with an average price target of $56.75, which is a 48.6% upside from current levels. In a report released today, Mizuho Securities also maintained a Buy rating on the stock with a $58 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $62.75 and a one-year low of $33.43. Currently, Zogenix has an average volume of 793.5K.
Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zogenix, Inc. is a pharmaceutical compan. It engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include ZX008 and Relday.
Read More on ZGNX:
